{"id":"csa-atg-herombopag","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Hemorrhage"},{"rate":null,"effect":"Renal toxicity"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Serum sickness (ATG-related)"},{"rate":null,"effect":"Thrombosis (eltrombopag-related)"}]},"_chembl":{"chemblId":"CHEMBL3038082","moleculeType":"Protein","molecularWeight":"1361.89"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cyclosporine A (CsA) is a calcineurin inhibitor that suppresses T-cell mediated immune responses, while anti-thymocyte globulin (ATG) provides additional immunosuppression by depleting T lymphocytes. Eltrombopag (Herombopag) is a thrombopoietin receptor agonist that stimulates megakaryocyte development and platelet production. Together, they address both the immune-mediated bone marrow failure and thrombocytopenia characteristic of aplastic anemia.","oneSentence":"This combination therapy suppresses the immune system while promoting platelet production to treat aplastic anemia.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:31:30.005Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Aplastic anemia (immunosuppressive therapy-naïve or relapsed/refractory)"}]},"trialDetails":[{"nctId":"NCT06009965","phase":"PHASE4","title":"Efficacy of IST Combined With TPO-RA in the Treatment of AA and Establishment of a Recurrence Prediction System","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2023-01-20","conditions":"Aplastic Anemia, CSA, Drug Therapy","enrollment":210}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SAA group intervention treatment"],"phase":"marketed","status":"active","brandName":"CsA+ATG+Herombopag","genericName":"CsA+ATG+Herombopag","companyName":"Peking Union Medical College Hospital","companyId":"peking-union-medical-college-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination therapy suppresses the immune system while promoting platelet production to treat aplastic anemia. Used for Aplastic anemia (immunosuppressive therapy-naïve or relapsed/refractory).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}